Related references
Note: Only part of the references are listed.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor in Development for the Treatment of Type 2 Diabetes Mellitus: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Escalating Doses in Healthy Adult Male Japanese Subjects
Akiko Sarashina et al.
CLINICAL THERAPEUTICS (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
DPP-4 inhibitors: What may be the clinical differentiators?
John Gerich
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Can Therapies That Target the Incretin System Improve Our Ability to Treat Type 2 Diabetes?
Thaddeus J. Bell et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION (2010)
The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets
R. Lupi et al.
REGULATORY PEPTIDES (2010)
Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture
Christian Toso et al.
TRANSPLANT INTERNATIONAL (2010)
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide
Renate E. van Genugten et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Improvement of Glucose Metabolism After a Pancreatoduodenectomy
Takao Ohtsuka et al.
PANCREAS (2009)
Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice
S. Merani et al.
ENDOCRINOLOGY (2008)
Distal pancreatectomy: Incidence of postoperative diabetes
Jonathan King et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
Nasser Mikhail
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
Carolyn F. Deacon
DIABETES OBESITY & METABOLISM (2007)
Effect of exenatide on β cell function after islet transplantation in type 1 diabetes
Khalid Al Ghofaili et al.
TRANSPLANTATION (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy - Results of a prospective, randomized, controlled trial
M Tani et al.
ANNALS OF SURGERY (2006)
Type of gastrointestinal reconstruction affects postoperative recovery after pancreatic head resection
Masahiko Kawamoto et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY (2006)
Insulin secretory defect plays a major role in the development of diabetes in patients with distal pancreatectomy
BW Lee et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes
JF Gautier et al.
DIABETES & METABOLISM (2005)
Long-term follow-up of glucose tolerance function after pancreaticoduodenectomy: Comparison between pancreaticogastrostomy and pancreaticojejunostomy
O Ishikawa et al.
SURGERY (2004)
Comparison of recovery of gastric phase III motility and gastric juice output after different types of gastrointestinal reconstruction following pylorus-preserving pancreatoduodenectomy
S Takahata et al.
JOURNAL OF GASTROENTEROLOGY (2002)
Effect of gastrointestinal reconstruction on quality of life and nutritional status after pylorus-preserving pancreatoduodenectomy
T Ohtsuka et al.
DIGESTIVE DISEASES AND SCIENCES (2002)
Pancreatic resection: Effects on glucose metabolism
LA Slezak et al.
WORLD JOURNAL OF SURGERY (2001)
Share Paper
